Heron Therapeutics (NASDAQ:HRTX) Cut to “Strong Sell” at Zacks Research

Zacks Research cut shares of Heron Therapeutics (NASDAQ:HRTX) from a hold rating to a strong sell rating in a report released on Thursday,Zacks.com reports.

HRTX has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Heron Therapeutics in a research report on Friday, January 9th. Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Heron Therapeutics presently has an average rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Price Performance

HRTX stock opened at $1.19 on Thursday. Heron Therapeutics has a 52-week low of $1.00 and a 52-week high of $2.68. The business has a fifty day moving average of $1.30 and a two-hundred day moving average of $1.27. The stock has a market cap of $218.20 million, a price-to-earnings ratio of -9.15 and a beta of 1.25. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. The company had revenue of $40.59 million during the quarter, compared to analyst estimates of $39.53 million. As a group, research analysts anticipate that Heron Therapeutics will post -0.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of HRTX. PKS Advisory Services LLC acquired a new stake in shares of Heron Therapeutics during the third quarter worth $25,000. Advisory Services Network LLC lifted its stake in shares of Heron Therapeutics by 2,383.4% in the 4th quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 18,114 shares during the period. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Heron Therapeutics in the second quarter valued at about $26,000. Jones Financial Companies Lllp raised its holdings in Heron Therapeutics by 5,541.2% during the third quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 23,661 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in Heron Therapeutics by 39.1% in the fourth quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 6,858 shares during the period. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics News Roundup

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Q4 results and company guidance: Heron reported Q4 revenue of $40.59M and EPS of ($0.02), both modest beats vs. Street estimates, and reported full‑year 2025 net revenue of $154.9M (65% YoY growth driven by ZYNRELEF and APONVIE). Management issued FY2026 net revenue guidance of $173–$183M and adjusted EBITDA guidance of $10–$20M — a clear near‑term commercial growth signal. Heron Press Release
• Positive Sentiment: HC Wainwright reiterates Buy and $6 target: Analyst B. Folkes continues to rate HRTX a Buy and models a multi‑year recovery to profitability (FY2027+), including an eventual FY2030 EPS of $0.55 — signaling meaningful upside from current levels if execution and product growth continue. (HC Wainwright research note)
• Neutral Sentiment: HC Wainwright near‑term modeling: The firm provided detailed Q1–Q4 2026 EPS estimates (Q1 -$0.03, Q2 -$0.02, Q3 -$0.01, Q4 $0.00) and a FY2026 consensus around -$0.13 — useful visibility but not an immediate catalyst. (HC Wainwright research note)
• Neutral Sentiment: Coverage and takeaways from the quarter are circulating: earnings call highlights and analyst write‑ups summarize the beat, commercial momentum, and guidance. These pieces help investors parse the quarter but largely echo the company release. Earnings Call Highlights Zacks Analysis WTOP Snapshot
• Negative Sentiment: Modest medium‑term EPS downgrades from HC Wainwright: The analyst trimmed FY2027, FY2028 and FY2029 EPS forecasts slightly (FY2027 to $0.14 from $0.15; FY2028 to $0.39 from $0.43; FY2029 to $0.44 from $0.48). Those cuts reduce some of the upside implied by prior estimates and may have tempered enthusiasm after recent share gains. (HC Wainwright research note)

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.